睿知中国疾病研究地图
候选清单0

北京首都医科大学

首都医科大学附属北京地坛医院

Beijing Ditan Hospital, Capital Medical University

在本站收录的 53 种疾病中,这家医院列在其中 6 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

首都医科大学附属北京地坛医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma72 篇牵头论文
  2. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  3. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  4. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  5. 原发性胆汁性胆管炎Primary biliary cholangitis11 篇牵头论文
  6. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 72 篇,占 0.5%。

牵头论文
72
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 161620212022: 161620222023: 111120232024: 8820242025: 21212025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  2. 正在招募
    InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07848750

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后局部治疗(消融、TACE、HAIC)免疫与靶向药物
论文中的科室消化/肝病科肿瘤内科病理/检验科普外/肝胆胰外科
牵头的论文72
  1. Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study.2025Acta oncologica (Stockholm, Sweden)免费全文
  2. Comprehensive Analysis of Oncogenic, Prognostic, and Immunological Roles of FANCD2 in Hepatocellular Carcinoma: A Potential Predictor for Survival and Immunotherapy.2025Biomedical and environmental sciences : BES
  3. Mono-TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First-Line Treatment of Lenvatinib: A Real-World Study.2025Cancer medicine免费全文
  4. Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial.2025Chinese journal of integrative medicineRCT
  5. The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.2025Clinical and experimental medicine免费全文
  6. FoxO1 as a Hub in Immunosenescence Induced by Hepatocellular Carcinoma and the Effect of Yangyin Fuzheng Jiedu Prescription.2025Drug design, development and therapy免费全文
  7. Systemic immune classification related to immune exhaustion evaluates the clinical response of patients with HBV-HCC after transarterial chemoembolization.2025Frontiers in immunology免费全文
  8. Featured intestinal microbiota associated with hepatocellular carcinoma in various liver disease states.2025Frontiers in immunology免费全文
  9. Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study.2025Frontiers in immunology免费全文
  10. Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration.2025Gut microbes免费全文
  11. Mechanism of Jiedu Prescription in Hepatocellular Carcinoma: Integrating Network Pharmacology and Experimental Validation.2025Integrative cancer therapies免费全文
  12. Value of CD8+ T cell-related genes and IL-6/STAT3 signaling pathway in the prognosis of HCC and experimental investigation.2025International journal of biological macromolecules
  13. Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.2025International journal of nanomedicine免费全文
  14. Application of Nanotechnology in TACE Treatment of Liver Cancer.2025International journal of nanomedicine免费全文
  15. Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer.2025International journal of nanomedicine免费全文
  16. Machine learning-based hepatocellular carcinoma risk prediction model for patients with HBV-related compensated advanced chronic liver disease.2025Journal of cancer research and clinical oncology免费全文
  17. Mechanism of Shashen-Maidong herb pair in treating hepatocellular carcinoma using network pharmacology and experimental validation.2025Journal of ethnopharmacology
  18. Loss of FAM172A gene prompts cell proliferation in liver regeneration.2025Molecular and cellular biochemistry
  19. Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up.2025Virologica Sinica免费全文
  20. CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma.2025World journal of gastroenterology免费全文
  21. Machine learning model using immune indicators to predict outcomes in early liver cancer.2025World journal of gastroenterology免费全文
  22. Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.2024Cancer science免费全文
  23. Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Astragalus-Atractylodes Herb Pair in Treating Hepatocellular Carcinoma.2024Drug design, development and therapy免费全文
  24. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.2024Frontiers in immunology免费全文
  25. Prognostic value of CD8+T cells related genes and exhaustion regulation of Notch signaling pathway in hepatocellular carcinoma.2024Frontiers in immunology免费全文
  26. Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors.2024Human vaccines & immunotherapeutics免费全文
  27. A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma.2024Scandinavian journal of gastroenterology
  28. Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma.2024Virulence免费全文
  29. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.2024World journal of gastroenterology免费全文
  30. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.2023BMC cancer免费全文
  31. Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.2023BMC cancer免费全文
  32. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.2023BMC gastroenterology免费全文
  33. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.2023Cancer immunology, immunotherapy : CII免费全文
  34. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.2023Cancer medicine免费全文
  35. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.2023Cancer medicine免费全文
  36. D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.2023Clinics and research in hepatology and gastroenterology
  37. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.2023European journal of medical research免费全文
  38. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.2023Frontiers in cellular and infection microbiology免费全文
  39. S100A11 Promotes Metastasis via AKT and ERK Signaling Pathways and Has a Diagnostic Role in Hepatocellular Carcinoma.2023International journal of medical sciences免费全文
  40. Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma.2023The oncologist免费全文
  41. Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts.2022Annals of hepatology
  42. Long-term outcomes of hepatectomy or radiofrequency ablation associated with splenectomy for the treatment of hepatocellular carcinoma and esophagogastric variceal bleeding.2022Asian journal of surgery
  43. Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.2022BMC cancer免费全文
  44. The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model.2022BMC cancer免费全文
  45. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.2022Cancer biology & therapy免费全文
  46. Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line.2022Cellular and molecular biology (Noisy-le-Grand, France)
  47. Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis.2022Frontiers in cellular and infection microbiology免费全文
  48. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma.2022Frontiers in immunology免费全文
  49. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.2022Frontiers in immunology免费全文
  50. Safety and efficacy of percutaneous microwave ablation using combined computed tomography and ultrasound-guided imaging in patients with hepatocellular carcinoma: A retrospective study.2022Journal of cancer research and therapeutics
  51. Liver abscess after microwave ablation of hepatocellular carcinoma caused by Clostridium perfringens.2022Journal of infection in developing countries
  52. Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma.2022Journal of nanobiotechnology免费全文
  53. Effect of decoction of Fuzheng Jiedu Xiaoji formula plus chemoembolization on primary liver cancer in patients.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen panRCT免费全文
  54. The association between several autophagy-related genes and their prognostic values in hepatocellular carcinoma: a study on the foundation of TCGA, GEPIA and HPA databases.2022Molecular biology reports
  55. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.2022Technology in cancer research & treatment免费全文
  56. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.2022The Cochrane database of systematic reviews免费全文
  57. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy.2021BMC cancer免费全文
  58. Gene Polymorphism of MUC15, MMP14, BRAF, and COL1A1 Is Associated with Capsule Formation in Hepatocellular Carcinoma.2021Canadian journal of gastroenterology & hepatology免费全文
  59. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.2021CancerRCT
  60. A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer.2021Cancer immunology research
  61. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.2021Clinics and research in hepatology and gastroenterology
  62. Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.2021European journal of gastroenterology & hepatology
  63. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  64. Prognostic value of liver stiffness measurement in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation: a meta-analysis.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  65. Effect of microwave ablation on platelet and coagulation function in patients with BCLC-A hepatocellular carcinoma.2021Journal of cancer research and therapeutics
  66. TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma.2021Oncoimmunology免费全文
  67. Yangyin Fuzheng Jiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  68. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.2021Phytomedicine : international journal of phytotherapy and phytopharmacologyRCT
  69. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation.2021Reproductive biology
  70. The development of a predictive risk model on post-ablation hemobilia: a multicenter matched case-control study.2021The British journal of radiology免费全文
  71. Hepatocellular carcinoma with type II-III portal vein tumour thrombosis: treatment using transarterial chemoembolisation and microwave ablation.2021The British journal of radiology免费全文
  72. Imaging features and outcomes in patients with ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization: a retrospective clinical study.2021The Journal of international medical research免费全文
中文论文(未计入)4
  1. [Exploring the advantages of traditional Chinese medicine and dual-anti therapy for liver cirrhosis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Fuzheng Huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils/lymphocytes].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Effects of anti-liver fibrosis treatment on the occurrence of liver cancer in patients with hepatitis B-related liver cirrhosis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [The progress and challenges in immunotherapy for the difficulty- to- treat liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)状态不明NCT05152498牵头方早期I期2021-01 启动
  2. A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis状态不明NCT04301908牵头方2020-04 启动
  3. Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)状态不明NCT05088733牵头方早期I期2020-07 启动
  4. Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio状态不明NCT05154812牵头方早期I期2020-10 启动
  5. Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT状态不明NCT04127396牵头方IV期2019-09 启动
  6. Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter已完成NCT04264962牵头方早期I期2017-01 启动
  7. Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma已完成NCT02927626牵头方早期I期2016-08 启动
  8. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  9. InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma正在招募NCT07848750研究中心2026-06 启动
  10. A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma进行中,不再招募NCT07713290研究中心I期2025-04 启动
  11. Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma已完成NCT07845266研究中心I期2024-04 启动
  12. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  13. Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC状态不明NCT04157140研究中心II期2019-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 9 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 11 篇,占 3.7%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 2220242025: 332025

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科病理/检验科
牵头的论文11
  1. Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis.2026Annals of hepatology
  2. Systemic inflammatory response index: a novel predictor for cardiovascular disease risk in patients with primary biliary cholangitis.2025European journal of medical research
  3. Real-world performance of transient elastography in assessing advanced fibrosis in Chinese patients with primary biliary cholangitis.2025World journal of gastroenterology
  4. Multi-omics analysis reveals gut microbiota-metabolite interactions and their association with liver function in autoimmune overlap syndrome.2025World journal of gastroenterology
  5. High C-reactive protein-to-albumin ratio levels are associated with osteoporosis in patients with primary biliary cholangitis.2024Frontiers in endocrinology
  6. Machine learning-based characterization of the gut microbiome associated with the progression of primary biliary cholangitis to cirrhosis.2024Microbes and infection
  7. Clinical significance of serum antinuclear antibodies in patients with autoimmune hepatitis and comorbidity.2023Clinical and experimental medicine
  8. Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.2023World journal of gastroenterology
  9. Methylation of the HCBP6 promoter is associated with primary biliary cholangitis pathogenesis.2022Biochemical and biophysical research communications
  10. The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism.2022Frontiers in immunology
  11. Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study.2021Canadian journal of gastroenterology & hepatology
中文论文(未计入)1
  1. [Clinicopathological features of Sjogren's syndrome complicated with liver injury].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
早期论文(2016–2020 年)2
  1. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.2018European journal of gastroenterology & hepatology
  2. [Effect of ursodeoxycholic acid with traditional Chinese medicine on biochemical response in patients with primary biliary cholangitis: a real-world cohort study].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  2. Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression即将招募NCT07733882研究中心2026-08 启动
  3. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis正在招募NCT07387549研究中心III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京地坛医院

Beijing Ditan Hospital, Capital Medical University

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Beijing Ditan Hospital; Beijing Ditan Hospital Affiliated to Capital Medical University; Beijing Ditan Hospital Capital Medical University; Capital Medical University Affiliated Beijing Ditan Hospital; Capital Medical University Beijing Ditan Hospital; Beijing Ditan Hosipital; China Capital Medical University Beijing Ditan Hospital; Beijing First Infectious Diseases Hospital

提出更正下载数据